somatotroph is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-07-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
The peptide backbone corresponds to GRF(1-29), the first 29 residues of native growth hormone-releasing hormone, which retains most of the receptor-activating activity of the full-length molecule. Four substitutions distinguish the analog from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes slow cleavage by dipeptidyl peptidase IV, the enzyme that degrades native hormone in plasma within minutes. The outcome is improved enzymatic stability combined with a still brief residence time when no additional modification is present.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
Gas: Volatile vapors often used for fuel. Charcoal: The solid carbon residue remaining in the kiln. Liquid distillate: The condensed vapors that form the basis for further refinement. Separation of the liquid: The liquid distillate naturally separates (or is processed) into two distinct layers:
==== Section D: Storage and Transport ==== Section D ON Storage and Transport of the IIR is involved in the controlled-temperature logistics and distribution of temperature-sensitive products, from foodstuffs to health products (medicines, vaccines, blood products, organs, etc.), from artwork to chemicals. It addresses all issues of equipment and solutions for a durable cold chain from the production or manufacture to the consumption or use of these products. Section D thus covers the issues of storage, transportation by land, air or water, packaging, distribution and delivery of these products to the consumer, and the traceability of the cold chain. The Section is involved in warehouse and platform equipment, devices for temperature-controlled transport, coolants or cool packs, small coolers and refrigerated containers, chillers, refrigerated furnishings, refrigerated cabinets, climate chambers, refrigerators and freezers, but also in thermometers and temperature recorders. The cold chain involves many temperature ranges, both positive and negative, from -80°C to + 63°C.
On 20 October 2001, an element of ODA 595 guided in the first JDAM bomb from a B-52, impressing General Dostum and his Northern Alliance forces who soon used it for Psychological warfare – taunted the Taliban over their radio frequencies. On 9 November 2001, ODA 595 and ODA 534 and the seven members of the CIA's Special Activities Division assisted about 2000 members of the Northern Alliance who attacked and liberated Mazari Sharif on horseback, foot, pickup trucks, and BMP armored personnel carriers. On November 11, in the central north of Afghanistan, ODA 586 was advising General Daoud Khan outside the city of Taloqan and coordinating a batch of preparatory airstrikes when the General surprised everyone by launching an impromptu massed infantry assault on the Taliban holding the city. Before the first bomb could be dropped, the city fell. On 12 and 13 November, ODA 555 assisted the Northern Alliance forces in the capture of Kabul. On November 14, 2001, ODA 574 and Hamid Karzai inserted into Uruzgan Province via 4 MH-60K helicopters and later fought the Battle of Tarwinkot with a small force of guerrillas. On 23 November, ODA 586 assisted General Daoud Khan forces in the taking Kunduz. On 25 November, a headquarters element from 3rd Battalion, 5th SFG, along with British SBS and other US forces took part in the Battle of Qala-i-Jangi, on 27 November, during a CAS mission, 5 Green Berets were wounded by a misdirected JDAM. Various ODA's took part in the taking of Kandahar.
Sources: en.wikipedia.org
=== Radiation processes === Some proponents for the authenticity of the Shroud of Turin have argued that the image on the shroud was created by some form of radiation emission at the "moment of resurrection". However, the STURP member Alan Adler has stated that this theory is not generally accepted as scientific, given that it runs counter to the laws of physics, while agreeing that the darkening of the fabric could be produced by exposure to light (and predicting that despite the fact that the Shroud is normally stored in darkness and rarely displayed, it will eventually become darker in the future). Raymond Rogers also criticized the theory, saying: "It is clear that a corona discharge (plasma) in air will cause easily observable changes in a linen sample. No such effects can be observed in image fibers from the Shroud of Turin. Corona discharges or plasmas made no contribution to image formation." Even if ultraviolet radiation were proven to have formed the image, it cannot be proven that it was not natural, that of the sun, applied to the prepared cloth unevenly to create the image. Others have hypothesized that an earthquake after Jesus’ death could have released a burst of neutrons that irradiated the shroud and changed some of the nuclei to different isotopes by neutron capture.
== Clinical presentation == Patients with hemoglobin H disease present with chronic hemolytic anemia that ranges in severity from mild to moderate disease. Anemia is the most common presenting symptom of patients with HbH disease. Other common clinical features include jaundice, splenomegaly, hepatomegaly, and gallstones. All of these symptoms are related to the destruction of the red blood cells in the spleen and the associated increased hemoglobin metabolism. Patients with non-deletional HbH disease are more likely to be symptomatic and have severe disease presentation when compared to individuals with deletional HbH disease. Disease presentation varies from asymptomatic individuals to neonatal growth retardation and death in the most severe cases. Death in the neonatal period occurs due to the severe anemia resulting in hydrops fetalis. Patients most often present initially due to hemolytic episodes that occur during times of infection or inflammation. During these episodes, patients may develop hemolytic crisis, in which there is a rapid drop in the hemoglobin due to increased red blood cell destruction.
The muscle cell is damaged by the depletion of ATP and possibly the high temperatures, and cellular constituents "leak" into the circulation, including potassium, myoglobin, creatine, phosphate and creatine kinase. The other known causative gene for MH is CACNA1S, which encodes an L-type voltage-gated calcium channel α-subunit. There are two known mutations in this protein, both affecting the same residue, R1086. This residue is located in the large intracellular loop connecting domains 3 and 4, a domain possibly involved in negatively regulating RYR1 activity. When these mutant channels are expressed in human embryonic kidney (HEK 293) cells, the resulting channels are five times more sensitive to activation by caffeine (and presumably halothane) and activate at 5–10mV more hyperpolarized. Furthermore, cells expressing these channels have an increased basal cytosolic Ca2+ concentration. As these channels interact with and activate RYR1, these alterations result in a drastic increase of intracellular Ca2+, and, thereby, muscle excitability. Other mutations causing MH have been identified, although in most cases the relevant gene remains to be identified.
=== Epigenetic studies === As more research is conducted on determinants of longevity, the impact of genetics and lifestyle are becoming an important question. Scientists have been looking for the genetic and molecular processes that affect aging. Recent research shows that a relationship exists between aging and genes that work on keeping cells healthy and support their most basic functions, cell metabolism and maintenance. By measuring the biological age of various tissues from centenarians, researchers may be able to identify tissues that are protected from aging effects. According to a study of 30 different body parts from centenarians and younger controls, the cerebellum is the youngest brain region (and probably body part) in centenarians (about 15 years younger than expected) according to an epigenetic biomarker of tissue age known as epigenetic clock. These findings could explain why the cerebellum exhibits fewer neuropathological hallmarks of age related dementias compared to other brain regions. Further, the offspring of semi-supercentenarians (subjects who reached an age of 105–109 years) have a lower epigenetic age than age-matched controls (age difference=5.1 years in peripheral blood mononuclear cells) and centenarians are younger (8.6 years) than expected based on their chronological age.
Sources: en.wikipedia.org
Despite the acquisitions by big tobacco companies, some independent e-cigarette companies had more success, most notably Juul Labs, as of 2018. As of 2018, 95% of e-cigarettes were made in China. Despite international growth of e-cigarettes during the 2010s, not all regions around the world have yet embraced it as much. In 2018, Indonesia became only one of the first in Asia or the Global South to recognise e-cigarettes as a genuine alternative to smoking tobacco.
The government also introduced facilitation measures for international media, including visa-on-arrival arrangements for foreign journalists covering the talks and shuttle transport services between designated media area, Jinnah Convention Centre, and Serena Hotel.
therapeutic area) might be tempted or encouraged to expand their engagement with that CRO into other, unrelated areas; however, caution is required as CROs are always seeking to expand their experience and success in one area cannot reliably predict success in unrelated areas that might be new to the organization.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.